Sign In
Buy PRNB
$100.05
+0 (+0%)
At Close: May 27, 2022
Principia Biopharma Reports Fourth Quarter and Full Year 2019 Financial Results
08:01pm, Tuesday, 10'th Mar 2020
SOUTH SAN FRANCISCO, Calif., March 10, 2020 -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for.
Earnings Preview: Principia Biopharma Inc. (PRNB) Q4 Earnings Expected to Decline
04:30pm, Tuesday, 10'th Mar 2020
Principia Biopharma Inc. (PRNB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Principia Biopharma Inc. (PRNB) Q4 Earnings Expected to Decline
04:30pm, Tuesday, 10'th Mar 2020
Principia Biopharma Inc. (PRNB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Barclays PLC Grows Stake in Principia Biopharma Inc (NASDAQ:PRNB)
08:54am, Tuesday, 10'th Mar 2020
Barclays PLC lifted its stake in shares of Principia Biopharma Inc (NASDAQ:PRNB) by 128.5% in the fourth quarter, Holdings Channel reports. The firm owned 23,408 shares of the company’s stock after
ValuEngine Upgrades Principia Biopharma (NASDAQ:PRNB) to "Hold"
07:58am, Sunday, 08'th Mar 2020
Principia Biopharma (NASDAQ:PRNB) was upgraded by investment analysts at ValuEngine from a “sell” rating to a “hold” rating in a report issued on Friday, ValuEngine reports. PRNB has been the
Martin Babler Sells 15,000 Shares of Principia Biopharma Inc (NASDAQ:PRNB) Stock
09:52am, Saturday, 07'th Mar 2020
Principia Biopharma Inc (NASDAQ:PRNB) CEO Martin Babler sold 15,000 shares of Principia Biopharma stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of
Principia Biopharma Inc (NASDAQ:PRNB) Expected to Post Earnings of -$0.74 Per Share
10:25am, Friday, 28'th Feb 2020
Equities research analysts predict that Principia Biopharma Inc (NASDAQ:PRNB) will post ($0.74) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have
American International Group Inc. Purchases 3,064 Shares of Principia Biopharma Inc (NASDAQ:PRNB)
09:20am, Friday, 28'th Feb 2020
American International Group Inc. grew its position in shares of Principia Biopharma Inc (NASDAQ:PRNB) by 36.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the
Healthcare Faces A Contagion
02:36pm, Thursday, 27'th Feb 2020
Fear mounts as investors brace for a viral outbreak in the US. Volatility to remain high as Covid-19 virus remains an unknown threat. Impact on earnings outlook
FIL Ltd Purchases New Stake in Principia Biopharma Inc (NASDAQ:PRNB)
11:44am, Thursday, 27'th Feb 2020
FIL Ltd purchased a new stake in Principia Biopharma Inc (NASDAQ:PRNB) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fir
Fmr LLC Has $269.41 Million Stock Position in Principia Biopharma Inc (NASDAQ:PRNB)
11:42am, Wednesday, 26'th Feb 2020
Fmr LLC lifted its stake in shares of Principia Biopharma Inc (NASDAQ:PRNB) by 36.8% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,9
Jennison Associates LLC Makes New Investment in Principia Biopharma Inc (NASDAQ:PRNB)
11:28am, Sunday, 23'rd Feb 2020
Jennison Associates LLC purchased a new position in shares of Principia Biopharma Inc (NASDAQ:PRNB) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange
Zacks Investment Research Lowers Principia Biopharma (NASDAQ:PRNB) to Sell
02:28pm, Thursday, 20'th Feb 2020
Principia Biopharma (NASDAQ:PRNB) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Thursday, Zacks.com reports. Acc
Principia Biopharma Inc.: Setting The Record Straight On BTK Inhibition
02:15pm, Wednesday, 19'th Feb 2020
Contrary to Sanofi's claims, BTK inhibition does not shut off B cells. Principia's MS drug does not penetrate the brain effectively. BTK inhibition likely makes
Principia to Present at 9th Annual SVB Leerink Global Healthcare Conference
01:01pm, Wednesday, 19'th Feb 2020
Principia Biopharma Inc. (PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated diseases, today announced that management will participate in the SVB
